gymnasterkoreayne B: from Gymnaster koraiensis; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 10264498 |
| CHEMBL ID | 452639 |
| MeSH ID | M0582600 |
| Synonym |
|---|
| (5s,6z)-1-(3-methyloxiran-2-yl)tetradeca-6,13-dien-1,3-diyn-5-ol |
| CHEMBL452639 |
| gymnasterkoreayne b |
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Quinone oxidoreductase | Mus musculus (house mouse) | Drug uptake | 7.3800 | 7.3800 | 7.3800 | 7.3800 | AID546826 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID546826 | Induction of NADPH:quinone reductase activity in mouse Hepa-1c1c7 cells assessed as drug level required to double specific enzyme activity | 2010 | Bioorganic & medicinal chemistry letters, Dec-15, Volume: 20, Issue:24 | SAR studies of gymnasterkoreayne derivatives with cancer chemopreventive activities. |
| AID546825 | Cytotoxicity against mouse Hepa-1c1c7 cells | 2010 | Bioorganic & medicinal chemistry letters, Dec-15, Volume: 20, Issue:24 | SAR studies of gymnasterkoreayne derivatives with cancer chemopreventive activities. |
| AID546824 | Chemoprevention index, ratio of IC50 for mouse Hepa-1c1c7 cells to drug level required to double specific NADPH:quinone reductase activity in mouse Hepa-1c1c7 cells | 2010 | Bioorganic & medicinal chemistry letters, Dec-15, Volume: 20, Issue:24 | SAR studies of gymnasterkoreayne derivatives with cancer chemopreventive activities. |
| AID335514 | Cytotoxicity against mouse L1210 cells after 48 hrs by WST-1 assay | 2002 | Journal of natural products, Jun, Volume: 65, Issue:6 | Gymnasterkoreaynes A-F, cytotoxic polyacetylenes from Gymnaster koraiensis. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.84) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||